RESUMEN
Evidence for specific and direct bacterial product recognition through toll-like receptors (TLRs) has been emphasized recently. We analyzed lipopeptide analogues and enterobacterial lipopolysaccharide (eLPS) for their potential to activate cells through TLR2 and TLR4. Whereas bacterial protein palmitoylated at its N-terminal cysteine and N-terminal peptides derived thereof are known to induce TLR2-mediated cell activation, a synthetic acylhexapeptide mimicking a bacterial lipoprotein subpopulation for which N-terminal trimyristoylation is characteristic (Myr(3)CSK(4)) activated cells not only through TLR2 but also through TLR4. Conversely, highly purified eLPS triggered cell activation through overexpressed TLR2 in the absence of TLR4 expression if CD14 was coexpressed. Accordingly, TLR2(-/-) macrophages prepared upon gene targeting responded to Myr(3)CSK(4) challenge, whereas TLR2(-/-)/TLR4(d/d) cells were unresponsive. Through interferon-gamma (IFNgamma) priming, macrophages lacking expression of functional TLR4 and/or MD-2 acquired sensitivity to eLPS, whereas TLR2/TLR4 double deficient cells did not. Not only TLR2(-/-) mice but also TLR4(-/-) mice were resistant to Myr(3)CSK(4) challenge-induced fatal shock. d-Galactosamine-sensitized mice expressing defective TLR4 or lacking TLR4 expression acquired susceptibility to eLPS-driven toxemia upon IFNgamma priming, whereas double deficient mice did not. Immunization toward ovalbumin using Myr(3)CSK(4) as adjuvant was ineffective in TLR2(-/-)/TLR4(-/-) mice yet effective in wild-type, TLR2(-/-), or TLR4(-/-) mice as shown by analysis of ovalbumin-specific serum Ig concentration. A compound such as Myr(3)CSK(4) whose stimulatory activity is mediated by both TLR2 and TLR4 might constitute a preferable adjuvant. On the other hand, simultaneous blockage of both of the two TLRs might effectively inhibit infection-induced pathology.
Asunto(s)
Proteínas Bacterianas/farmacología , Lipopolisacáridos/farmacología , Macrófagos Peritoneales/inmunología , Ácido Mirístico/farmacología , Péptidos/farmacología , Receptor Toll-Like 2/inmunología , Receptor Toll-Like 4/inmunología , Adyuvantes Inmunológicos/farmacología , Animales , Proteínas Bacterianas/inmunología , Células Cultivadas , Enterobacteriaceae/inmunología , Galactosamina/farmacología , Humanos , Interferón gamma/farmacología , Receptores de Lipopolisacáridos/inmunología , Lipopolisacáridos/inmunología , Antígeno 96 de los Linfocitos/inmunología , Activación de Macrófagos/efectos de los fármacos , Activación de Macrófagos/inmunología , Macrófagos Peritoneales/citología , Ratones , Ratones Noqueados , Ácido Mirístico/inmunología , Péptidos/inmunología , Choque/inducido químicamente , Choque/inmunología , Receptor Toll-Like 2/agonistas , Receptor Toll-Like 2/deficiencia , Receptor Toll-Like 4/agonistas , Receptor Toll-Like 4/deficienciaRESUMEN
Cellular recognition of immuno-stimulatory microbial products alarming the host immune system upon infection, as well as endogenous molecular patterns representing perturbation of regular homeostasis such as through necrosis of host cells is mediated by innate pattern recognition receptors to which toll-like receptors (TLRs) belong. A variety of agonists has been attributed to TLR2. We raised monoclonal antibodies (mAbs) toward the murine TLR2 extracellular domain (mT2ECD) in order to analyze murine TLR2 expression. Murine macrophages were stained TLR2-specifically with distinct mAbs as shown by flow cytometry, immuno precipitation, and immuno-cytochemical analysis. TLR2-specific murine macrophage activation was inhibited through pre-incubation with a mAb mT2.4 while another mTLR2-specific mAb mT2.7 did not affect cell activation through TLR2. Plasmon resonance based analysis showed inhibition of lipopeptide binding to mT2ECD if complex formation with mT2.4 preceded binding analysis. Systemic induction of IL-6, IL-12p40, and GROalpha/KC release to the serum upon lipopeptide challenge of mice was inhibited by systemic administration of mT2.4. Furthermore, 120 mg/kg of mT2.4 protected mice from lethal shock-like syndrome in an experimental low-dose model of septic shock. This result validates blockage of cell surface TLR2 for inhibition of immune cell over-activation upon microbial challenge.
Asunto(s)
Anticuerpos Monoclonales/inmunología , Anticuerpos Monoclonales/farmacología , Receptores Inmunológicos/antagonistas & inhibidores , Receptores Inmunológicos/metabolismo , Animales , Línea Celular , Humanos , Ratones , Ratones Noqueados , Receptores Inmunológicos/deficiencia , Receptores Inmunológicos/genética , Tasa de Supervivencia , Receptor Toll-Like 2RESUMEN
Toll-like receptors (TLRs) mediate activation of the immune system upon challenge with microbial agonists, components of disintegrating cells of the body, or metabolic intermediates of lipidic nature. Comparison of murine (m) and human (h) TLR2 primary sequences revealed 65% of identical residues within the extracellular domains in contrast to 84% in the intracellular domains. Comparative analysis of TLR2-driven cell activation by various TLR2 agonists showed that the tri-lauroylated lipopeptide analog (Lau(3)CSK(4)) is recognized efficiently through mTLR2 but not hTLR2. Genetically complemented human embryonic kidney 293 cells and murine TLR2(-/-) embryonic fibroblasts, as well as human and murine macrophage cells, were used for this analysis. In contrast to cellular activation, which depended on blockable access of the TLR2-ligand to TLR2, cellular uptake of Lau(3)CSK(4) and tri-palmitoylated peptide (P(3)CSK(4)) was independent of TLR2. A low-conserved region spanning from leucine-rich repeat (LRR) motif 7 to 10 was found to control TLR2 species-specific cell activation. Exchange of mLRR8 for hLRR8 in mTLR2 abrogated mTLR2-typical cell activation upon cellular challenge with Lau(3)CSK(4) but not P(3)CSK(4), implicating mLRR8 as a central element of Lau(3)CSK(4) recognition. The point mutation L112P within LRR3 abrogated hTLR2-dependent recognition of lipopeptides but merely attenuated mTLR2 function, whereas deletion of the N-terminal third of each LRR-rich domain (LRRs 1 to 7) had the opposite effect on P(3)CSK(4) recognition. Despite similar domain structure of both TLR2 molecules, species-specific properties thus exist. Our results imply distinct susceptibilities of humans and mice to challenge with specific TLR2 ligands.
Asunto(s)
Ácidos Grasos/química , Ácidos Grasos/metabolismo , Glicoproteínas de Membrana/metabolismo , Péptidos/metabolismo , Receptores de Superficie Celular/metabolismo , Animales , Línea Celular , Fibroblastos/citología , Fibroblastos/fisiología , Genes Reporteros , Humanos , Macrófagos/citología , Macrófagos/metabolismo , Glicoproteínas de Membrana/genética , Ratones , Ratones Noqueados , Estructura Molecular , Mutación , Péptidos/química , Receptores de Superficie Celular/genética , Homología de Secuencia de Ácido Nucleico , Transducción de Señal/fisiología , Receptor Toll-Like 2 , Receptores Toll-LikeRESUMEN
Hyperactivation of immune cells by bacterial products through toll-like receptors (TLRs) is thought of as a causative mechanism of septic shock pathology. Infections with Gram-negative or Gram-positive bacteria provide TLR2-specific agonists and are the major cause of severe sepsis. In order to intervene in TLR2-driven toxemia, we raised mAb's against the extracellular domain of TLR2. Surface plasmon resonance analysis showed direct and specific interaction of TLR2 and immunostimulatory lipopeptide, which was blocked by T2.5 in a dose-dependent manner. Application of mAb T2.5 inhibited cell activation in experimental murine models of infection. T2.5 also antagonized TLR2-specific activation of primary human macrophages. TLR2 surface expression by murine macrophages was surprisingly weak, while both intra- and extracellular expression increased upon systemic microbial challenge. Systemic application of T2.5 upon lipopeptide challenge inhibited release of inflammatory mediators such as TNF-alpha and prevented lethal shock-like syndrome in mice. Twenty milligrams per kilogram of T2.5 was sufficient to protect mice, and administration of 40 mg/kg of T2.5 was protective even 3 hours after the start of otherwise lethal challenge with Bacillus subtilis. These results indicate that epitope-specific binding of exogenous ligands precedes specific TLR signaling and suggest therapeutic application of a neutralizing anti-TLR2 antibody in acute infection.
Asunto(s)
Glicoproteínas de Membrana/antagonistas & inhibidores , Receptores de Superficie Celular/antagonistas & inhibidores , Choque Séptico/inmunología , Choque Séptico/prevención & control , Animales , Anticuerpos Monoclonales/farmacología , Secuencia de Bases , Línea Celular , ADN Complementario/genética , Epítopos/genética , Epítopos/metabolismo , Humanos , Mediadores de Inflamación/metabolismo , Ligandos , Activación de Macrófagos , Glicoproteínas de Membrana/deficiencia , Glicoproteínas de Membrana/genética , Glicoproteínas de Membrana/metabolismo , Ratones , Ratones Noqueados , Receptores de Superficie Celular/deficiencia , Receptores de Superficie Celular/genética , Receptores de Superficie Celular/metabolismo , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/inmunología , Proteínas Recombinantes de Fusión/metabolismo , Choque Séptico/etiología , Transducción de Señal , Receptor Toll-Like 2 , Receptores Toll-Like , Factor de Necrosis Tumoral alfa/biosíntesisRESUMEN
Toll-like receptors (TLRs) mediate microbial pattern recognition in vertebrates. A broad variety of agonists has been attributed to TLR2 and three TLRs, TLR4, TLR2, and TLR5, have been demonstrated to bind microbial products. Distinct agonists might interact with different subdomains of the TLR2 extracellular domain. The TLR2 extracellular domain sequence includes 10 canonical leucine-rich repeat (LRR) motifs and 8-10 additional and potentially functionally relevant LRR-like motifs. Thus, the transfection of TLR2 LRR/LRR-like motif deletion constructs in human embryonic kidney 293 cells and primary TLR2-deficient mouse fibroblasts was performed for analysis of the role of the regarding domains in specific pattern recognition. Preparations applied as agonists were highly purified soluble peptidoglycan, lipoteichoic acid, outer surface protein A from Borrelia burgdorferi, synthetic mycoplasmal macrophage-activating lipoprotein-2, tripalmitoyl-cysteinyl-seryl-(lysyl)3-lysine (P3CSK4), dipalmitoyl-CSK4 (P2-CSK4), and monopalmitoyl-CSK4 (PCSK4) as well as lipopolysaccharide and inactivated bacteria. We found that a block of the N-terminal seven LRR/LRR-like motifs was not involved in TLR2-mediated cell activation by P3CSK4 and P2CSK4 ligands mimicking triacylated and diacylated bacterial polypeptides, respectively. In contrast, the integrity of the TLR2 holoprotein was compulsory for effective cellular recognition of other TLR2 agonists applied, including PCSK4. The formation of a functionally relevant subdomain by a region including the N-terminal seven LRR/LRR-like motifs rather than by single LRRs is suggested by our results. They further imply that TLR2 contains multiple binding domains for ligands that may contribute to the characterization of its promiscuous molecular pattern recognition.